Rocket releases positive results from Leukocyte Adhesion Deficiency-I trial
Interim Phase I/II trial results show Rocket’s ex vivo lentiviral…
Interim Phase I/II trial results show Rocket’s ex vivo lentiviral gene therapy candidate, RP-L201, is safe and of benefit to paediatric patients with severe Leukocyte Adhesion Deficiency-I.